Targeting Rare Genomic Alterations in Advanced Thyroid Cancer: What Endocrinologists Need to Know

Targeting Rare Genomic Alterations in Advanced Thyroid Cancer: What Endocrinologists Need to Know is organized by Clinical Care Options (CCO), LLC.,Released: March 15, 2023,Expiration: March 14, 2024,Program Learning Goal:,The goal of this activity is to improve the knowledge, competence, and performance of learners to assess new and emerging biomarkers and planning individualized treatment for patients with thyroid cancer.,Learning Objectives:,Upon completion of this activity, participants should be able to:,• Order appropriate assays or molecular tests to detect oncogenic gene fusions in patients with thyroid cancer,• Appraise emerging clinical data supporting the use of TRK inhibition in NTRK fusion–positive thyroid cancer and RET inhibition in RET-altered thyroid cancer ,• Manage treatment-related symptoms associated with the treatment of RET-altered or NTRK fusion–positive cancer,• Refer eligible patients with NTRK fusion–positive and RET-altered thyroid cancer for ongoing clinical trials